By transforming bacteria with a plasmid that encodes a synchronized lysis circuit (SLC) molecule plus a nanobody antagonist of CD47 (CD47nb), the authors were able to selectively release the therapeutic agent in to tumour cells in vivo. Here, CD47 is linked to neoplasm.